STRO Q3 2026 STRO-006 Phase 1 Initiation First patient dosed in October 2026, Beat Guidance by +2023.0
STRO beat prior Q3 2026 STRO-006 Phase 1 Initiation guidance by +2023.0. Sutro Biopharma reported Q3 2026 revenue of $9.1 million, down 6% year-over-year from $9.7 million in Q3 2025, with the decrease driven by lower collaboration revenue. Net loss improved to $31.5 million or -$1.90 per share compared to a net loss of $56.9 million or -$6.66 per share in the prior-year period. The company initiated STRO-006 Phase 1 with first patient dosed in October 2026, meeting its Q3 2026 guidance milestone, and expects it...
Read source-backed brief